Abstract. Background/objectives: Recent data suggest a role for heparanase in several proteinuric conditions. An increased glomerular heparanase expression is associated with loss of heparan sulfate in the glomerular basement membrane (GBM
INTRODUCTION

D
iabetic nephropathy (DN) is a major lifethreatening complication of diabetes, that is the leading cause of end-stage renal disease in developed countries [1, 2] . Abnormal perm-selectivity of the glomerular basement membrane (GBM) plays an important role in the pathogenesis of DN [3, 4] . The glomerular basement membrane (GBM) consists mainly of laminin, type IV collagen, and heparan sulfate proteoglycans (HSPGs). Heparan sulfate proteoglycans (HSPGs) are abundant in the extracellular matrices (ECMs) including basement membranes, and consist of diverse core polypeptides and the HS [5, 6] . In patients with DN, loss of Heparan sulfate proteoglycans from theglomerular extracellu-lar matrices has been reported [7] . Heparan sulfate maintains the mechanical integrity of the glomerular basement membranes. Direct heparitinase digestion by the heparitinase existing in glomerular basement membranes results in a loss of membrane function [8] . Heparanase, an endoglycosidase, is the predominant enzyme that specifi cally cleaves heparan sulfate, the main polysaccharide of the GBM [3, 9] . In patients with DN, loss of HSPG in glomerular extracellular matrices of diabetic kidney has been reported and this reduction was associated with increased glomerular expression of heparanase [7] . An increase in urinary heparanase activity was observed in both type 1 and type 2 diabetic patients with proteinuria [10] . In the early phase of human Diabetic nephropathy, there is a urinary loss of albumin, consistent with a loss of heparan sulfates in the glomerular basement membrane [11] . Therefore, loss of heparan sulfates in the GBM results in a decrease of the anionic charge barrier and may possibly be resulting in progression of proteinuria and deterioration of renal function in the DN [11, 12] .
Well known heparanase-1 inhibitors are heparin(s) and sulodexide, a low-molecular weight heparin / dermatan sulphate blend, which is eff ective in the treatment of DN. Sulodexide is a mixture of glycosaminoglycans composed of a 80% fast mobility heparin fraction and 20% dermatan sulfate. Sulodexide diff ers from other glycosaminoglycans, like heparin, because does not have anti-coagulation properties when given orally and have a longer half-life [13, 14] . Treatment with sulodexide has been shown to reduce proteinuria in patients with DN [15, 16] . However, data from a recent controlled trial showed negative results [17] . As mentioned above the eff ect of sulodexide on urine protein and glycosaminoglycan excretion is not exactly clear. In the present study, we investigated the eff ect of a heparanase inhibitor (sulodexide) on urine excretion of protein and glycosaminoglycan and on renal histology in type I diabetic nephropathy.
MATERIAL AND METHODS
Experimental design: Fifteen male 10 week-old Wistar rats weighing 230 ± 20 g were purchased by the animal house of the Urmia University of Medical Sciences, Urmia, Iran. All procedures on the animals were conducted in accordance with the Principles of Laboratory Animal Care and approved by the Ethical Committee of the Urmia University of Medical Sciences. The animals were housed under standard conditions (21 ± 2°C and 12/12 hr light/dark cycle). The animals were fed with normal rat diet and water.
Animal grouping: The animals were divided into three groups (fi ve animals each): Group 1  healthy controls (0.5 ml of NS, daily, gavage), Group 2  diabetic group, and Group 3-diabetic group treated with sulodexide (1/5 mg/kg; daily, gavage). Diabetes was induced by a single dose of streptozotocin (STZ, 50 mg/kg BW, dissolved in saline. ip). Five days after the STZ injection, blood glucose levels were determined with a glucose strip test and a glucometer. Rats with blood glucose levels above 250 mg/dL were defi ned as the diabetic animals. The treatment started on the 21st day after the STZ injection since we found a signifi cant increase in urine protein excretion (UPE) rate in the diabetic rats in comparison with the control rats. The treatment was continued daily for three weeks.
For twenty one days after the STZ injection, the rats were kept individually in metabolic cages (8 AM-2 PM) and urine samples were collected for 6-h measurement of UPE [18] and urine creatinine. The observations revealed a signifi cant increase in the UPE rate in the diabetic rats in comparison with the control rats and the animals were considered nephropathic.
At the end of the sixth week, 6-h urine samples were collected for biochemical analysis. Then, fi ve rats from each subgroup were sacrifi ced under ether anesthesia. Moreover, blood samples were collected by cardiac puncture and tissue samples were stored in formalin.
Biochemical analyses: Serum BUN and creatinine were measured using an auto-analyzer. Additionally, a 6h urine sample was collected for measurement of BUN, Cr, UPE and glycosaminoglycan (GAG).
Urine protein excretion [18] was determined by a Pars Azmon kit (Iran). Further, UPE was measured by quantitative reaction with bromocresol green [28] using bovine serum albumin as standard. A sample volume of 10 μl and a validated standard were mixed separately with 1 ml of bromocresol green and then the absorbance was read at 625 nm.
Urinary GAG in the 6-hour urine samples was measured spectrophotometrically at a wavelength of 520 nm, with a colorimetric method described by Jong, [29] using 1.9 dimethyleneblue and bovine kidney heparan sulfate as standard (Sigma Cat No H7640).
Histological study: At the end of the study the right kidney was removed and stored in 10% formaldehyde. Kidney sections (5 mm) were stained with periodic acid-Schiff (PAS) and Masson's trichrome (MTC) for histologic and morphometric analysis. Mesangial matrix accumulation was assessed by PAS-positive staining in nuclei-free areas of the mesangium. The mesangial matrix was evaluated in 30 randomly selected glom-eruli and scored in a blinded way on a scale of 0 to 4, where 0 = 0-5%, 1 = 0.5-25%, 2 = 25-50%, 3 = 50-75%, and 4 = > 75% deposition. The scores revealed variations in the extent rather than in the intensity of staining [30] . The "sclerotic index" referred to the mean score. Collagen deposition was measured by Masson's trichrome staining of 30 glomeruli, scored in a blinded way using the above-mentioned system and expressed as an arbitrary unit [30, 31] . Then, it was expressed as a mean sclerotic index and glomerular collagen staining score for each group.
Statistical analysis: Data were expressed as means ± SDs. Statistical signifi cance of diff erences was assessed by one-way ANOVA on the SPSS (Version 18; SPSS Inc., Chicago, USA) followed by Tukey's test. A p-value of less than 0.05 was considered statistically signifi cant. Linear regression analyses were applied to evaluate the relationship between two variables.
RESULTS
Eff ects of Sulodexide administration on serum BUN, Creatinine, K and glucose
The results show signifi cantly increased levels of serum BUN, Cr, K and glucose of the DN rats in comparison with the control (Table 1 & Figure 1 , p < 0.001). However, the administration of sulodexide in the DN decreased serum BUN, Cr, K and these changes were statistically signifi cant (Table 1, p < 0.01). Moreover, there was no signifi cant diff erence in the serum concentration of glucose between the DN and the sulodexide treated groups (Figure 1 ). All together, these data suggest that sulodexide was able to protect against the DN injury but did not signifi cantly aff ect the changes of serum glucose. 
Eff ects of Sulodexide on urine protein excretion and protein-creatinine ratio (PCR)
Three weeks after streptozotocin administration, urinary 6-hour protein excretion level was 9.1 ± 2.1, 55 ± 12.4 and 49.6 ± 18.3 mg/6h in the healthy controls, diabetics and treated diabetics, respectively. Urinary protein excretion increased signifi cantly in the diabetic rats (p < 0.01). Moreover, urinary 6-hour albumin excretion level remained high over time in the DN in comparison with the control group (p < 0.001). However, the administration of sulodexide signifi cantly reduced the urine 6-h protein excretion (p < 0.001) in the DN in comparison with the untreated DN group (Table 1) . The results showed a positive eff ect of sulodexide on the STZ-induced DN in the rats, which was evidenced by the signifi cant decrease (p < 0.001) in the urinary protein/creatinine ratio (Figure 2 ).
Eff ects of Sulodexide on urine glycosaminoglycan GAG
At the end of the six study weeks, 6-hour urinary glycosaminoglycan (GAG) levels were signifi cantly higher in the DN rats in comparison with the healthy controls (133.4 ± 20.2 and 44.2 ± 6.3 respectively; p < 0.001). However, the sulodexide treated group had a signifi cantly lower GAG excretion (97 ± 16.4) than the untreated DN rats (p < 0. 01, Figure 3) .
Correlation of urinary protein with urinary glycosaminoglycan excretion:
Urinary protein excretion was signifi cantly correlated with urinary glycosaminoglycan excretion (r = 0.88, p < 0.001) in all the study groups ( Figure 4 ).
Eff ects of Sulodexide on morphological changes after diabetic nephropathy (DN) injury:
Diabetic nephropathy led to increased glomerular surface area, mesangial expansion, thickening of the GBM and Bowman's capsule, and increased deposition of matrix proteins within the mesangial matrix ( Figure 5 and 6 ). The "sclerotic index", which refl ects glomerular matrix accumulation, increased in DN rats in comparison with the controls (2.75 ± 0.19 vs 0.23 ± 0.07, three weeks after onset of albuminuria, P < 0.001), but sulodexide treatment signifi cantly reduced (1.3 ± 0.1, p < 0.001) the sclerotic index ( Figure 5 ). Collagen deposition in the glomerulus was markedly reduced in the DN following the sulodexide treatment (2.29 ± 0.15 vs 0.83 ± 0.09, p < 0.001) ( Figure 6 ). As shown in Figures 5 and 6 , the pathological changes due to diabetic nephropathy were signifi cantly alleviated in the sulodexide treated DN rats. 
DISCUSSION
In the present study after STZ administration Wistar rats developed diabetes mellitus then pathological urine glycosaminoglycan and proteinuria excretion and also impaired kidney function. Rats with diabetic nephropathy showed predominantly increased glomerular surface area, mesangial expansion, thickening of the GBM and Bowman's capsule, and increased deposition of matrix proteins within the mesangial matrix but relatively mild tubulointerstitial changes. Our results are consistent with previous studies [19, 20] . Over the 6-week study, there was a signifi cant increase in the urinary protein excretion. Changes in heparan sulfate glycosaminoglycan chains were not investigated in the present study. However, according to the results of previous studies a loss of heparan sulfate proteoglycans in the GBM contributes to proteinuria in glomerular diseases including DN [21, 22] . Therefore the suludexide as heparanase inhibitor might have prevented diabetic nephropathy  associated heparan sulfate loss and reduced proteinuria.
Although some previous studies showed that urinary excretion of sulfated polysaccharides were reduced in diabetic rats [23, 24] , the present study could not confi rm these fi ndings and our results confi rmed that urinary GAG excretion was elevated in the non-treated diabetic rats as shown before in diabetic rats by Reddi [18, 25] and in diabetic humans by McAuliff e [26, 27] and PopA [27] . The studies mentioned above suggested that this decreased urinary glycosaminoglycan concentration could be related to the decreased glycosaminoglycan contents of the kidneys and other tissues in diabetic animals, as reported by Cechowska-Pasko et al. [28] , but it could also be due to altered renal permselectivity to negatively charged molecules. As noted, the results of the present study showed that urinary GAG excretion was elevated in the non-treated diabetic rats and sulodexide (haparanase inhibitor) treatment signifi cantly decreased urinary GAG excretion in DN rats compared with the non-treated DN rats. Urinary GAG excretion was signifi cantly correlated with the protein excretion in all the study groups. Since urinary GAG levels correlated with urinary protein concentration, it is possible that the glomerular basement membrane is leaky for these substances. Decreased GAG level in GBM of kidney results in its leakiness leading to proteinuria [29] . The decrease in GAG levels in the kidney could be due to decreased synthesis or increased degradation. How decreased glomerular synthesis caused increased urine excretion of GAGs is not clearly understood. An increase in heparanase activity, an enzyme which is known to degrade GAGs such as heparin sulfate, was found to increase in glomeruli of diabetic rats [30] . As previously mentioned, increase in urinary GAGs during diabetes negatively correlated whit kidney GAGs. This could refl ect increased GAG degradation as well as changes in kidney GAGs and their increased urine excretion . Diabetic nephropathy kidney tissue showed progressive glomerular and tubular fi brosis as a fi nal pathway, which eventually aff ects all substructures in the kidney. The present study provided evidence that the inhibition of the heparanase was functionally signifi cant, which resulted in reduced proteinuria, ECM accumulation and collagen deposition in the glomeruli in vivo.
In conclusion, the sulodexide (haparanase inhibitor) treatment reduced urinary GAG and protein excretion, prevented GBM thickness and collagen deposition and probably protected from the loss of GBM anionic content in DN rats. Preservation of GAG and anionic charges of the GBM seems to be one of the mechanisms by which sulodexide ameliorates the renal histological and functional changes in diabetic rats.
